Market Place
Sourcing Support
Adlai Nortye Announces Completion of Patient Enrollment in PIII of Buparlisib
17 Nov 2023 //
GLOBENEWSWIRE
Adlai Nortye`s Buparlisib Set to a Potential Treatment for Anti-PD-1 HNSCC
15 Mar 2019 //
PR NEWSWIRE
Novartis succeeds where Roche failed with PI3K breast cancer drug
23 Aug 2018 //
PHARMAPHORUM
Novartis just boasted of a big PhIII PI3K success
23 Aug 2018 //
ENDPTS
Novartis trial win lifts profile of new breast cancer drug
23 Aug 2018 //
REUTERS
Adlai Nortye announces Results From Buparlisib study in HNSCC published
30 Jul 2018 //
PR NEWSWIRE
FiercePharmaAsia—Biogen-Eisai, Otsuka, Samsung and more
13 Jul 2018 //
FIERCE PHARMA
Novartis hands off buparlisib to China`s Adlai Noryte
12 Jul 2018 //
FIERCE BIOTECH
Novartis punts a late-stage PI3K drug to China’s biotechs
12 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.